The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksHigh Impact•24 February 2026•

1 min read

Travere Therapeutics Reports Strong FY25 Growth and Profitability Ahead of FDA Decision

Key Facts

1Travere's FY25 revenue reached $410.5M, an 81% year-over-year increase.

2FILSPARI sales grew 144% YoY, driven by record patient starts.

3The company turned profitable in 4Q25 with a non-GAAP net income of $81.1M.

4A critical FDA PDUFA decision for FSGS is approaching in April.

Travere Therapeutics (TVTX) reported a standout fiscal year 2025, with total revenue surging 81% year-over-year to reach $410.5 million. The growth was primarily fueled by the commercial success of FILSPARI, which saw sales jump 144% alongside record levels of new patient starts. Significantly, the company achieved a major milestone by turning profitable in the fourth quarter, posting a non-GAAP net income of $81.1 million. This financial turnaround reflects both strong market demand and improved cost discipline across the organization. Investors are now shifting their focus toward April, when a critical FDA PDUFA decision regarding the FSGS treatment is expected. This upcoming regulatory catalyst, combined with solid fundamental growth, positions the biotech firm for a potentially transformative year.

Sources:

seekingalpha.com